Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury
Brief Summary: The purpose of the study is to explore to what extent continuing the antidepressant medication citalopram (Celexa), after depression has responded to treatment, helps prevent the return of depressive symptoms in patients with recent traumatic brain injury (TBI).


Options:
A: Inclusion Criteria:

1. The subject/patient is able to read and understand the subject/patient information sheet.
2. Prior to any screening procedures, the subject/patient must have signed the informed consent form. No study-related procedures may be performed before the subject/patient has signed the form.
3. Age 25-70 years
4. Heavy alcohol consumption (males more than 5 doses/ day, female more than 4 doses/day) for at least 10 years
5. Alcohol dependence (DSM-IV) assessed by SCID-I interview.
6. Major depression (DSM-IV) assessed by SCID-I interview. At least 4 weeks past from the previous inpatient treatment for AWS (alcohol withdrawal syndrome).

Exclusion Criteria:

1. Other drug dependence (screened by urine test)
2. Other serious mental illness (DSM-IV)
3. Hazard of suicide
4. Pregnancy
5. Serious kidney, hart or thyroid problem
6. The subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.
7. Liver cirrhosis or liver enzymes ASAT tai ALAT \>200.
8. The person that met the criteria stated in the Finnish Law on Clinical Studies, paragraph 7-10§ (children, pregnant, imamates or mentally handicapped).
B: - Outpatients aged 18 to 75 years old with nonpsychotic major depressive disorder (HAMD score 14 or greater)
C: Inclusion Criteria:

* Patients with a depressive episode
* HDRS score \> 18
* Written informed consent

Exclusion Criteria:

* suicidal risk \> 3
* severe organic illness
* other psychotropic drugs
D: Inclusion Criteria:

* Age \> 18 years
* TBI within the last year (this is consistent with clinic population)
* Mild TBI
* Written, informed consent
* Diagnosis of major depressive episode using the depression module of the Structured Clinical Interview for DSM-IV Axis I disorders (SCID-IV), and baseline 17-item Hamilton Depression (HAM-D) Rating Scale score of 16 and above (prior to selective serotonin reuptake inhibitor \[SSRI\] treatment)
* Response to citalopram 20 or 40mg/d, as defined as a reduction in baseline HAM-D of \>= 50%, and HAM-D score of 10 or below; or response to citalopram defined as not meeting DSM-IV criteria for major depression and Clinical Global Impression - severity of mildly ill, borderline ill, or normal and a Clinical Global Impression - improvement of much improved or very much improved impression.

Exclusion Criteria:

* Prior TBI or other focal brain disease (e.g., stroke, tumour)
* Significant acute medical illness including: drug overdose; severely disturbed liver, kidney, lung or heart function; anemia; hypothyroidism; uncontrolled diabetes; Parkinson's disease; Huntington's chorea; progressive supranuclear palsy; brain tumor; subdural hematoma; or multiple sclerosis.
* Current alcohol or substance abuse
* A brain computed tomographic (CT) scan revealing focal lesions that could not be interpreted as consistent with TBI
* Presence of premorbid psychiatric diagnosis of schizophrenia, dementia or bipolar disorder
* Prior episode of major depression in two years prior to TBI, based on SCID-IV interview
* Prior treatment with citalopram or contraindications to receiving treatment with citalopram

Answer: D